BioCentury | Nov 16, 2018
Tools & Techniques

Benchtop manufacturing gets smaller

...to engineer many types of alternative hosts to make a range of proteins.” Love cited GlycoFi Inc....
...out of academia with an innovative yeast-based protein production platform that could control protein glycosylation. GlycoFi...
...decided not to produce biosimilars in-house, spokesperson Pamela Eisele told BioCentury the company has incorporated GlycoFi’s...
BioCentury | Nov 15, 2018
Tools & Techniques

Benchtop manufacturing gets smaller

...to engineer many types of alternative hosts to make a range of proteins.” Love cited GlycoFi Inc....
...out of academia with an innovative yeast-based protein production platform that could control protein glycosylation. GlycoFi...
...decided not to produce biosimilars in-house, spokesperson Pamela Eisele told BioCentury the company has incorporated GlycoFi’s...
BioCentury | Feb 14, 2011
Company News

Arsanis management update

...and a director, also co-founder and CEO of Adimab LLC and co-founder and CSO of GlycoFi Inc....
BioCentury | Feb 10, 2011
Financial News

Arsanis raises $9.6 million

...of Arsanis as well as co-founder and CEO of Adimab and co-founder and CSO of GlycoFi Inc....
BioCentury | Jan 25, 2010
Finance

SVLS closes V fund

...fund include: selling Alantos to Amgen Inc. (NASDAQ:AMGN) for $300 million, a 6X return; selling GlycoFi inc....
BioCentury | Dec 22, 2008
Strategy

Similar is faster

...dipped its toe in the biologic waters in 2006 with its $400 million acquisition of GlycoFi Inc....
...revised its plans. Merck now hopes to accelerate the monetization of the acquisition by using GlycoFi's...
...like the Sandoz International GmbH generics unit of Novartis AG , and Teva Pharmaceuticals Inc. "GlycoFi...
BioCentury | Dec 15, 2008
Company News

Merck pharmaceuticals news

...division would use the yeast-based glyco-engineering technology that the company gained through its acquisition of GlycoFi Inc....
BioCentury | Dec 10, 2008
Top Story

Merck forms follow-on biologics unit

...division would use the yeast-based glyco-engineering technology that the company gained through its acquisition of GlycoFi...
BioCentury | Nov 10, 2008
Finance

Biotech exits

...acquired Lorantis in 2005. In 2008, Celldex merged with Avant Immunotherapeutics, newco renamed Celldex (NASDAQ:CLDX). GlycoFi...
BioCentury | May 5, 2008
Strategy

Buying biology

...Adnexus Bristol-Myers (NYSE:BMY) $505 Protein engineering 2007 Domantis GlaxoSmithKline (LSE:GSK; NYSE:GSK) $455 Protein engineering 2006 GlycoFi...
Items per page:
1 - 10 of 49
BioCentury | Nov 16, 2018
Tools & Techniques

Benchtop manufacturing gets smaller

...to engineer many types of alternative hosts to make a range of proteins.” Love cited GlycoFi Inc....
...out of academia with an innovative yeast-based protein production platform that could control protein glycosylation. GlycoFi...
...decided not to produce biosimilars in-house, spokesperson Pamela Eisele told BioCentury the company has incorporated GlycoFi’s...
BioCentury | Nov 15, 2018
Tools & Techniques

Benchtop manufacturing gets smaller

...to engineer many types of alternative hosts to make a range of proteins.” Love cited GlycoFi Inc....
...out of academia with an innovative yeast-based protein production platform that could control protein glycosylation. GlycoFi...
...decided not to produce biosimilars in-house, spokesperson Pamela Eisele told BioCentury the company has incorporated GlycoFi’s...
BioCentury | Feb 14, 2011
Company News

Arsanis management update

...and a director, also co-founder and CEO of Adimab LLC and co-founder and CSO of GlycoFi Inc....
BioCentury | Feb 10, 2011
Financial News

Arsanis raises $9.6 million

...of Arsanis as well as co-founder and CEO of Adimab and co-founder and CSO of GlycoFi Inc....
BioCentury | Jan 25, 2010
Finance

SVLS closes V fund

...fund include: selling Alantos to Amgen Inc. (NASDAQ:AMGN) for $300 million, a 6X return; selling GlycoFi inc....
BioCentury | Dec 22, 2008
Strategy

Similar is faster

...dipped its toe in the biologic waters in 2006 with its $400 million acquisition of GlycoFi Inc....
...revised its plans. Merck now hopes to accelerate the monetization of the acquisition by using GlycoFi's...
...like the Sandoz International GmbH generics unit of Novartis AG , and Teva Pharmaceuticals Inc. "GlycoFi...
BioCentury | Dec 15, 2008
Company News

Merck pharmaceuticals news

...division would use the yeast-based glyco-engineering technology that the company gained through its acquisition of GlycoFi Inc....
BioCentury | Dec 10, 2008
Top Story

Merck forms follow-on biologics unit

...division would use the yeast-based glyco-engineering technology that the company gained through its acquisition of GlycoFi...
BioCentury | Nov 10, 2008
Finance

Biotech exits

...acquired Lorantis in 2005. In 2008, Celldex merged with Avant Immunotherapeutics, newco renamed Celldex (NASDAQ:CLDX). GlycoFi...
BioCentury | May 5, 2008
Strategy

Buying biology

...Adnexus Bristol-Myers (NYSE:BMY) $505 Protein engineering 2007 Domantis GlaxoSmithKline (LSE:GSK; NYSE:GSK) $455 Protein engineering 2006 GlycoFi...
Items per page:
1 - 10 of 49